{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:54:09Z","timestamp":1769795649485,"version":"3.49.0"},"reference-count":34,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001858","name":"Vinnova","doi-asserted-by":"crossref","award":["2021-01737"],"award-info":[{"award-number":["2021-01737"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Therapeutic drug monitoring (TDM) is a promising strategy to personalize chemotherapy dosing, especially for agents with narrow therapeutic indices such as epirubicin. However, widespread adoption is hindered by logistical challenges associated with venous blood sampling and centralized laboratory workflows. Objective: This study aimed to perform a method-comparison validation of the True Dose\u00ae TD-EPI microsampling kit by verifying analytical agreement between capillary and venous epirubicin measurements in real patient samples. The study focuses on analytical performance and does not constitute validation of the whole decentralized workflow, including unsupervised patient self-sampling. Methods: 13 patients with early-stage breast cancer receiving the first cycle of neoadjuvant or adjuvant epirubicin were enrolled. Capillary samples were collected using the finalized TD-EPI kit (Cap-TD) at 2.5 h (n = 13) and\/or 48 h (n = 10) post-infusion and stored at room temperature for 72 h before analysis. Matched venous samples were analyzed using both conventional protein precipitation (\u201cTraditional\u201d) and a modified lab-based True Dose workflow (Lab-TD). Epirubicin concentrations were quantified via validated liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS\/MS). Results: Cap-TD concentrations showed strong agreement with Traditional venous values (r = 0.953), with minimal bias (mean difference = 0.013 \u03bcM) in Bland\u2013Altman analysis. Passing\u2013Bablok regression confirmed analytical equivalence. Intra-assay variability remained within ICH M10 guidelines (CV \u2264 15%), and recovery was unaffected by 72 h ambient storage. Lab-TD results closely matched Traditional workflows, supporting reproducibility. Conclusions: The TD-EPI kit enables accurate decentralized monitoring of epirubicin, eliminating the need for venous access, cold-chain logistics, or in-clinic sampling. These findings support its integration into personalized oncology care and future applications in home-based TDM. Trial Registration: This study is part of an approved protocol registered in the EU Clinical Trials Register (EUCT Number 2024-514818-12-00; EudraCT Number 2017-000641-44; registration date: 15 June 2017).<\/jats:p>","DOI":"10.3390\/ph19020226","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:04:46Z","timestamp":1769612686000},"page":"226","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Method-Comparison Validation of a Novel Capillary Blood Collection Kit, True Dose\u00ae TD-EPI, for Therapeutic Drug Monitoring of Epirubicin"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1077-7907","authenticated-orcid":false,"given":"Serena","family":"De Chiara","sequence":"first","affiliation":[{"name":"True Dose AB, 171 65 Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nektarios","family":"Komninos","sequence":"additional","affiliation":[{"name":"True Dose AB, 171 65 Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-8114","authenticated-orcid":false,"given":"Oscar P. B.","family":"Wiklander","sequence":"additional","affiliation":[{"name":"Unit for Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institute, 171 77 Stockholm, Sweden"},{"name":"Breast Center, Karolinska, Comprehensive Cancer Center, Karolinska University Hospital, 171 76 Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Rydberg","sequence":"additional","affiliation":[{"name":"True Dose AB, 171 65 Solna, Sweden"},{"name":"Department of Oncology-Pathology, Karolinska Institute, 171 77 Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-4332","authenticated-orcid":false,"given":"Elham","family":"Hedayati","sequence":"additional","affiliation":[{"name":"Department of Oncology-Pathology, Karolinska Institute, 171 77 Solna, Sweden"},{"name":"Department of Oncology, South General Hospital, 118 83 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/jamaoncol.2022.4452","article-title":"All Optimal Dosing Roads Lead to Therapeutic Drug Monitoring\u2014Why Take the Slow Lane","volume":"8","author":"Beumer","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0959-8049(02)00151-X","article-title":"Dosing strategies for anticancer drugs: The good, the bad and body-surface area","volume":"38","author":"Felici","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/15622975.2018.1439595","article-title":"TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians","volume":"19","author":"Schoretsanitis","year":"2018","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ajhp\/zxaa128","article-title":"Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and \u03b2-lactam antibiotics to maximize effectiveness and minimize toxicity","volume":"77","author":"Cusumano","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s41409-024-02413-0","article-title":"A practical guide to therapeutic drug monitoring in busulfan: Recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"59","author":"Domingos","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1038\/s41598-021-81662-1","article-title":"Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study","volume":"11","author":"Gernaat","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bmt.2016.322","article-title":"Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients","volume":"52","author":"Andersson","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/1078-0432.CCR-10-1636","article-title":"Therapeutic drug monitoring for the individualization of docetaxel dosing: A randomized pharmacokinetic study","volume":"17","author":"Engels","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-019-05294-w","article-title":"Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database","volume":"177","author":"Helland","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1158\/1078-0432.CCR-22-3360","article-title":"Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"29","author":"Omlin","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40262-025-01492-6","article-title":"Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine","volume":"64","author":"Kicken","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-024-01399-8","article-title":"Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort","volume":"63","author":"Meertens","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41416-024-02789-2","article-title":"Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology\u2014An analysis of the closed cohorts of a multicentre prospective study","volume":"131","author":"Guchelaar","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41416-025-02954-1","article-title":"Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients","volume":"132","author":"Meertens","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/FTD.0000000000001315","article-title":"Clinical Application of Volumetric Absorptive Microsampling for Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs","volume":"47","author":"Meertens","year":"2025","journal-title":"Ther. Drug Monit."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Radovanovic, M., Galettis, P., Flynn, A., Martin, J.H., and Schneider, J.J. (2024). Paclitaxel and Therapeutic Drug Monitoring with Microsampling in Clinical Practice. Pharmaceuticals, 17.","DOI":"10.3390\/ph17010063"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1007\/s00216-024-05244-6","article-title":"Towards clinical adherence monitoring of oral endocrine breast cancer therapies by LC-HRMS\u2014Method development, validation, comparison of four sample matrices, and proof of concept","volume":"416","author":"Jacobs","year":"2024","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e70056","DOI":"10.1002\/bmc.70056","article-title":"Advancing Therapeutic Drug Monitoring for Oral Targeted Anticancer Drugs: From Hospital-Based Towards Home-Sampling","volume":"39","author":"Meertens","year":"2025","journal-title":"Biomed. Chromatogr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"461731","DOI":"10.1016\/j.chroma.2020.461731","article-title":"A review of recent advances in microsampling techniques of biological fluids for therapeutic drug monitoring","volume":"1635","author":"Tey","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"114443","DOI":"10.1016\/j.jpba.2021.114443","article-title":"Comparison of conventional dried blood spots and volumetric absorptive microsampling for tacrolimus and mycophenolic acid determination","volume":"208","author":"Lendoiro","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1200\/JCO.2012.44.2863","article-title":"Body-surface area-based chemotherapy dosing: Appropriate in the 21st century?","volume":"30","author":"Beumer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00280-005-0140-2","article-title":"Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients","volume":"58","author":"Lindman","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1158\/1078-0432.CCR-03-0538","article-title":"Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial","volume":"10","author":"Kisanga","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40262-024-01396-x","article-title":"Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial","volume":"63","author":"Alexandre","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/bcp.70006","article-title":"Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial","volume":"91","author":"Glewis","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/fcp.13037","article-title":"Evaluation of chemotherapy toxicities in patients receiving treatment for gastrointestinal cancers and therapeutic monitoring of 5-fluorouracil as a clinical support tool","volume":"38","author":"Antunes","year":"2024","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/17407745241232428","article-title":"The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing\u2014Challenging the \u201cmore is better\u201d dogma","volume":"21","author":"Loeser","year":"2024","journal-title":"Clin. Trials"},{"key":"ref_30","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2019). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: A patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet, 393, 1440\u20131452."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Brunsvig, P.F., Andersen, A., Aamdal, S., Kristensen, V., and Olsen, H. (2007). Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy. BMC Cancer, 7.","DOI":"10.1186\/1471-2407-7-197"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9973081","DOI":"10.1155\/bmri\/9973081","article-title":"Capillary Blood Self-Sampling for Therapeutic Drug Monitoring: A Mixed-Methods Usability Study of the True Dose\u00ae Kit","volume":"2025","author":"Crafoord","year":"2025","journal-title":"BioMed Res. Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"33331","DOI":"10.1038\/s41598-025-20951-5","article-title":"Development and evaluation of a novel capillary blood collection method for decentralized therapeutic drug monitoring using the True Dose kit","volume":"15","author":"Komninos","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_34","unstructured":"European Medicines Agency (2022). ICH Guideline M10 on Bioanalytical Method Validation: Step 5, European Medicines Agency."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/226\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:23:41Z","timestamp":1769750621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ph19020226"],"URL":"https:\/\/doi.org\/10.3390\/ph19020226","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}